

Appln. No. 10/761,370  
Amdt. dated January 3, 2006  
Reply to Office action of November 1, 2005

**REMARKS**

Claims 1 and 5 presently appear in this case. No claims have yet been examined on the merits. The official action of November 1, 2005, has now been carefully studied.

The examiner has required restriction among the following groups:

Group I, comprising claims 1 and 5, drawn to antibodies against RAP-2 and a method of using those antibodies;

Group II, comprising claims 2, 12 and 13, drawn to a method for modulating RIP activity using RAP-2 protein;

Group III, comprising claims 2-4, 12 and 13, drawn to a method for modulating RIP activity including in disease cells using DNA encoding RAP-2;

Group IV, comprising claims 6-8 and 11, drawn to antisense molecules and method of using those antisense molecules to modulate RIP activity;

Group V, comprising claim 10, drawn to a method for modulating RIP activity using ribozymes against RAP-2;

Group VI, comprising claim 14, drawn to a method of identifying RAP-2 interacting proteins with the yeast two-hybrid system; and

Group VII, comprising claims 15 and 16, drawn to methods of modulating RAP-2 function.

Appln. No. 10/761,370  
Amdt. dated January 3, 2006  
Reply to Office action of November 1, 2005


Applicants hereby elect the claims of Group I for prosecution. The non-elected claims have been cancelled without prejudice toward prosecution of the subject matter thereof in one or more divisional applications.

Prompt examination on the merits and allowance of claims now appearing in this case are earnestly urged.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

By

  
Roger L. Browdy  
Registration No. 25,618

RLB:rd  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528  
G:\BN\I\in12\Wallach27A\Pto\AmendmentA.doc